Crizotinib Current Events | Page 3

Crizotinib Current Events, Crizotinib News Articles.
Sort By: Most Viewed | Most Recent
Page 3 of 3 | 120 Results
UCI non-small cell lung cancer study highlights advances in targeted drug therapy
A UC Irvine oncologist's work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer. The results were published Thursday in the New England Journal of Medicine. (2010-11-01)

New therapy on the horizon for ALK+ non-small cell lung cancer
A new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who no longer respond to crizotinib -- the only approved ALK inhibitor. Results of this Novartis-sponsored sudy will be presented by a researcher from Fox Chase Cancer Center during the 2012 Annual Meeting of the American Society of Clinical Oncology on Sunday, June 3. (2012-06-01)

'Big data' approach helps pinpoint possible new stent drug to prevent heart attacks
Stanford University School of Medicine researchers hunting for a better drug coating for coronary stents, the small mesh tubes used to prop open plaque-filled arteries, have pinpointed a cancer drug as a possible candidate. (2014-11-17)

Cabozantinib most effective treatment for metastatic papillary kidney cancer
In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer - findings expected to change medical practice. (2021-02-13)

Study shows immunohistochemistry is reliable screening tool for ALK rearrangement
A recent study published in the January 2013 issue of the International Association for the Study of Lung Cancer's Journal of Thoracic Oncology, concludes immunohistochemistry is a reliable screening tool for identification of ALK rearrangement. (2012-12-15)

Alexander Levitzki of Hebrew University chosen for cancer research award
The American Association for Cancer Research has chosen professor Alexander Levitzki of the Hebrew University of Jerusalem as the winner of its 2013 Award for Outstanding Achievement in Chemistry in Cancer Research. (2013-04-08)

Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers
PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23. (2013-10-20)

CTCA Western clinical research director authors five innovative studies presented at ASCO
Advances in lung cancer, ovarian cancer and new immunotherapy treatments are among the scientific studies presented this year at ASCO by Dr. Glen Weiss, Director of Clinical Research at Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center (Western). Dr. Weiss has overseen a substantial number of innovative clinical trials since he began supervising clinical research at CTCA Western in 2013. (2016-06-03)

Cancer-causing mutation discovered in 1982 finally target of clinical trials
A recent article in the journal Cancer Discovery describes clinical trials at the University of Colorado Cancer Center and elsewhere that match drugs to long-overlooked oncogene, TRK, offering targeted treatment options for cancers that harbor these gene abnormalities. (2014-12-29)

Study details genes that control whether tumors adapt or die when faced with p53 activating drugs
When turned on, the gene p53 turns off cancer. However, when existing drugs boost p53, only a few tumors die -- the rest resist the challenge. A study published in the journal Cell Reports shows how: tumors that live even in the face of p53 reactivation create more of the protein p21 than the protein PUMA; tumors that die have more PUMA than p21. And, for the first time, the current study shows a handful of genes that control this ratio. (2013-05-22)

Nivolumab in advanced lung cancer: Indication of major added benefit
Patients with advanced nonsquamous NSCLC who have already undergone chemotherapy survive longer with the drug than with docetaxel. (2016-08-18)

ASCO releases studies from upcoming annual meeting
The American Society of Clinical Oncology today highlighted five studies in a press briefing from among more than 4,500 abstracts publicly posted online at abstract.asco.org in advance of ASCO's 47th Annual Meeting. (2012-05-16)

SWOG names 5 cancer researchers outstanding Young Investigators
SWOG, one of the nation's largest cancer clinical trial cooperative groups, has selected five talented researchers for its Young Investigators Training Course, an intensive, three-day workshop in how to develop and conduct cancer clinical trials. (2010-09-08)

Study examines FDA influence on design of pivotal drug studies
An examination of the potential interaction between pharmaceutical companies and the US Food and Drug Administration (FDA) to discuss future studies finds that one-quarter of recent new drug approvals occurred without any meeting, and when such meetings occurred, pharmaceutical companies did not comply with one-quarter of the recommendations made by the FDA regarding study design or primary outcome, according to a study in the Nov. 26 issue of JAMA. (2014-11-25)

NEJM reports positive results for larotrectinib against TRK-fusion cancer
55 patients representing 17 cancer types tested positive for TRK fusion and were treated with larotrectinib. Overall response rate was 75 percent. (2018-02-22)

Tobacco use makes precancerous cells that fertilize cancer growth
Inhibiting EGFR along with PI3K may negate EGFR escape route that precancerous cells provide to cancer cells to avoid PI3K inhibitors. (2019-04-01)

Study finds known lung cancer oncogenes ALK and ROS1 also drive colorectal cancer
A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients. (2013-12-17)

Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases
Pooled analysis of three phase 1 and 2 clinical trials show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC). (2019-12-13)

ALK, ROS1 and now NTRK1: Study shows prevalence of new genetic driver in lung cancer
ASCO study reports the prevalence of the NTRK1 mutation in an unselected population of 450 lung cancer samples, with >1 percent of patients testing positive. This and other work from Dr. Doebele's group forms the basis of a phase 1 clinical trial targeting NTRK1 mutations in advanced solid tumors (NCT02122913). (2014-05-31)

Mayo Clinic investigators pinpoint cause, possible treatment for rare form of sarcoma
Researchers at Mayo Clinic Center for Individualized Medicine have discovered a potential cause and a promising new treatment for inflammatory myofibroblastic tumors, a rare soft tissue cancer that does not respond to radiation or chemotherapy. (2016-11-22)

Clinical trial success influenced by biomarker- and receptor-targeted therapies in NSCLC
Over the past decade, a great clinical focus has been directed at developing new and innovative therapies for advanced non-small cell lung cancer (NSCLC). An analysis of clinical trials evaluating these therapies demonstrates that the cumulative success rate for new agents for advanced NSCLC is lower than the industry-estimated rate. However, biomarker- and receptor-targeted therapies were found to substantially increase clinical trial success. (2014-02-14)

ROS1 gene fusions are found in 2.4 percent of Asian patients with lung adenocarcinoma
ROS1 fusion genes were successfully detected independent of gender or smoking history in young East Asian patients with lung adenocarcinoma, a histological subgroup in non-small cell lung cancer, using multiplex reverse transcriptase-polymerase chain reaction and immunohistochemistry diagnostic tests. (2014-07-21)

Does stronger initial response to cancer treatment predict longer overall survival?
It seems like such a simple question: Do patients whose tumors shrink more in response to targeted treatment go on to have better outcomes than patients whose tumors shrink less? But the implications of a recent study demonstrating this relationship are anything but simple and could influence both the design of future clinical trials and the goals of oncologists treating cancer. (2017-08-14)

Combined inhibition of VEGF and c-MET can decrease metastasis
Dual inhibition of vascular endothelial growth factor and c-MET signaling inhibited tumor invasion and metastasis in a laboratory model of pancreatic neuroendocrine cancer, according to a paper published in Cancer Discovery. (2012-02-24)

Study shows how TRK-fusion lung cancer escapes LOXO-101, offering new treatment strategies
A University of Colorado Cancer Center study presented at the American Association for Cancer Research Annual Meeting 2016 pinpoints ways that cancer cells evolve to resist the drug LOXO-101 (2016-04-17)

Is your lung cancer really ROS1-negative?
CU Cancer Center study shows that three common laboratory tests used to determine ROS1 status may return false-negative results, meaning that some patients who could benefit from ROS1-directed therapy may be slipping through the cracks. (2018-08-08)

Chromosomal translocations point the way toward personalized cancer care
A recent University of Colorado Cancer Center review published in the journal Frontiers of Medicine shows the role of chromosomal translocations in causing a range of cancers. Emerging, personalized therapies target these translocations. (2012-08-13)

Lung cancer driver ALK-fusion found in melanoma
A University of Colorado Cancer Center study published today in the journal Molecular Cancer Therapeutics finds a genetic change called ALK-fusion in a patient sample of a melanoma subtype called mucosal melanoma. When researchers treated a tumor grown from this sample with the drugs crizotinib and ceritinib - both FDA approved to treat ALK-positive lung cancer - the tumor responded dramatically. (2017-10-23)

Molecular 'portraits' of tumors match patients with trials in everyday clinical practice
Researchers in France are taking advantage of the progress in genetic and molecular profiling to analyse the make-up of individual cancer patients' tumours and, using this information, assign them to particular treatments and phase I clinical trials -- an approach that could become part of everyday clinical practice. The research is presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland. (2012-11-08)

Rare pulmonary side effects of brigatinib often resolve without treatment discontinuation
'This study shows that [rare pulmonary side effects of brigatinib] can disappear within days despite continued exposure to the drug,' says D. Ross Camidge, M.D., Ph.D. (2019-05-21)

ENDO 18: New model, new drugs, and a 'remarkable' response in adrenal cancer
Two University of Colorado Cancer Center studies presented at ENDO 2018 use new models to identify genetic targets and test promising treatments in adrenal cancer. One patient was treated with the immunotherapy pembrolizumab and now more than a year after starting treatment remains on the drug with 77 percent tumor reduction and no new metastases. (2018-03-19)

Using online patient communities and new trial approaches to optimize clinical research
Dr. Howard West, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, and Dr. Ross Camidge, director of the Thoracic Oncology Clinical Program at the University of Colorado School of Medicine are looking for ways to help patients tackle these geographic barriers using both online patient communities and innovative trial approaches. (2012-02-15)

Pancreatic cancer: CD44 protein induces metastases
Due to their rapid metastatic spread, pancreatic tumors are among the most aggressive types of cancer. Less than five percent of patients have a survival rate of five years. KIT researchers have now established the basis for new therapeutic approaches. In the Gastroenterology journal they report that in various pancreatic cancer mouse models CD44v6-specific peptides do not only inhibit the spread of tumor cells, but may even lead to the regression of already existing metastases. (2015-11-10)

National lung matrix trial (NLMT)
The largest stratified medicine dataset of non-small cell lung cancer patients indicates further molecular stratifications could benefit from targeted therapies, according to research presented today at the IASLC 2019 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer. (2019-09-09)

Two Colorado studies find resistance mechanisms in ALK+ and ROS1+ cancers
In one of 12 ROS1+ samples and 15 of 43 ALK+ samples, new kinases had been altered to allow treatment resistance. However, 'we found a lot of stuff besides kinase mutations,' a researcher says. 'What we're trying to say is that resistance happens in a lot of different ways and we need to be thinking about all the genetic and non-genetic changes that can occur.' (2018-04-10)

Next-generation microscopy
A novel microscopy method allows unprecedented insights into the spatial organization and direct interactions of immune cells within blood and liquid multi-lineage tissues. The assay, called 'Pharmacoscopy,' is able to determine the immunomodulatory properties of drugs within large libraries on immune cells in high resolution and high throughput. Introduced in Nature Chemical Biology, Pharmacoscopy enables new possibilities for drug discovery, particularly in cancer immunotherapy, personalized medicine, and research on signaling pathways of the immune system. (2017-04-24)

Some patients with treatment-resistant colorectal cancers may have a new option
A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research. Preliminary data published in this study showed human tumors with MET amplification, grown in mice, responded to MET inhibitor drugs. (2013-06-02)

New general concept for the treatment of cancer
A team of researchers from five Swedish universities, led by Karolinska Institutet and the Science for Life Laboratory, have identified a new way of treating cancer. The concept is presented in the journal Nature and is based on inhibiting a specific enzyme called MTH1, which cancer cells, unlike normal cells, require for survival. Without this enzyme, oxidized nucleotides are incorporated into DNA, resulting in lethal DNA double-strand breaks in cancer cells. (2014-04-02)

New guidelines on clinical trial design for patients with brain metastases
New guidelines from an international, multidisciplinary group published in the journal Lancet Oncology describe how to most appropriately address cancer patients with CNS involvement within clinical trials of anti-cancer drugs. (2017-12-29)

Yale Cancer Center's tip sheet for the 50th Annual Meeting of ASCO May 30-June 3, 2014
The news items below are from oral presentations or poster sessions scheduled for the 50th annual ASCO conference. Yale Cancer Center will have experts available to speak with the media before or during ASCO. Abstracts cover immunotherapy for Melanoma and Bladder Cancer; PSMA; Breast Cancer Biomarkers; Cervical Cancer Screening; Non-Small Cell Lung Cancer; and Mental Health Comorbidities in VA Patients. (2014-05-23)

Page 3 of 3 | 120 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.